Skip to main content

Volume 6 Supplement 3

AIDS Vaccine 2009

P14-13. Long-term follow-up of study participants in HIV prophylactic vaccine clinical trials in Africa


The International AIDS Vaccine Initiative (IAVI) has conducted phase I and IIA HIV vaccine clinical trials in healthy HIV-uninfected African adults. Different recombinant DNA and vector-based vaccines encoding HIV-1 genes from subtypes A, B and C were tested. Between 2001 and 2006, 391 volunteers were enrolled in 5 countries at 8 collaborating centers. All vaccines tested were found to be generally safe and well-tolerated, with no vaccine-related serious adverse events reported. This study is designed to monitor any late health effects in prior study participants.


At the end of the clinical trial, enrollment into a long-term follow-up study is offered. Visits are scheduled 6-monthly. Follow-up is at least 5 years after the last vaccination. A health questionnaire is administered investigating any health problems, hospitalizations, new diagnoses of chronic disease, medications prescribed for more than 4 weeks, problems in the vaccinated arm(s), pregnancies and outcomes, and social harm. HIV testing is performed to detect incident HIV infection and/or to monitor persistence of vaccine-induced antibodies in HIV-uninfected volunteers testing HIV positive at final study visit.


So far, 242 individuals have been enrolled in long-term follow-up. To date, follow up is 301.2 person years. New diseases lasting over 4 weeks include dermatological (fungal infections), gastrointestinal and musculoskeletal conditions. Seventeen 17 pregnancies, 12 hospitalizations (mostly pregnancy-related) and 1 new HIV infection have been reported; 9 volunteers experienced some social harm. There were no congenital abnormalities. Vaccine induced antibodies were detected until 2 years and longer after final study visit.


No significant medical problems have been detected through long-term follow-up of HIV vaccine study participants. Overall, more than 92% of study participants report to be in good health at any visit. These data contribute to the long-term safety profile of HIV vaccines tested in healthy, HIV-negative African adults.

Author information

Authors and Affiliations


Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Schmidt, C., Jaoko, W., Kaleebu, P. et al. P14-13. Long-term follow-up of study participants in HIV prophylactic vaccine clinical trials in Africa. Retrovirology 6 (Suppl 3), P201 (2009).

Download citation

  • Published:

  • DOI: